Acute Porphyria Drug Database

J07BF03 - Poliomyelitis, Trivalent, Inactivated, Whole Virus
Propably not porphyrinogenic
PNP

Rationale
Based on the pharmacokinetics of the poliomyelitis, trivalent, inactivated, whole virus vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Inactivated polio virus type 1, 2 and 3.
Therapeutic characteristics
The poliomyelitis vaccine is indicated for the active immunization against poliomyelitis in infants, children and adults, for both primary immunization (2 or 3 doses) and for following booster doses. It is administered by intramuscular or deep subcutaneous injection.
Metabolism and pharmacokinetics
The poliomyelitis vaccine is not metabolized by the cytochrome P450 system.

References

  1. Government bodies
  2. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
  3. Summary of Product Characteristics
  4. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Imovax Polio. (Last edition: 31.06. 2014). #1879

Similar drugs
Explore alternative drugs in similar therapeutic classes J07B / J07BF or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙